AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017
Mar 1, 2017
31868_dirs_2017-03-01_e744aa97-0e72-42c5-a6c8-1ef77ac5f0fb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-02-27
Reporting Person: Barnes Alane P (VP, General Counsel & Corp Sec)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-27 | Emp. Stock Option (Right to Buy) | $5.51 | A | 150000 | Acquired | 2027-02-27 | Common Stock (150000) | Direct |
Footnotes
F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20